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Abstract
Background—Candida infections are a leading cause of infectious disease-related death in
infants supported with extracorporeal membrane oxygenation (ECMO). The ECMO circuit can
alter drug pharmacokinetics (PK), thus standard fluconazole dosing in children on ECMO may
result in suboptimal drug exposure. This study determined the PK of fluconazole in infants on
ECMO.
Methods—Infants <120 days old received either intravenous fluconazole prophylaxis (25 mg/kg
once a week) or treatment (12 mg/kg daily) while on ECMO. Paired plasma samples were
collected pre- and post-oxygenator around doses 1 and 2 to calculate PK indices and describe
oxygenator extraction. A 1-compartment model was fit to the data using non-linear regression.
Surrogate pharmacodynamic targets for efficacy were evaluated.
Results—Ten infants were enrolled. After dose 1 (n=9), the median clearance was 17 mL/kg/h,
the median volume of distribution was 1.5 L/kg, and the median exposure in the first 24 hours
(AUC0–24) was 322 h*mg/L. After multiple doses (n=7), the median clearance was 22 mL/kg/h,
the median volume of distribution was 1.9 L/kg, and the AUC0–24 was 352 h*mg/L. After dose 1,
78% of infants achieved the prophylaxis target, while only 11% achieved the therapeutic target.
Oxygenator extraction of fluconazole was minimal (−2.0%, standard deviation 15.0), and
extraction was not correlated with age of the ECMO circuit (rho= − 0.05). There were no adverse
events related to fluconazole.
Conclusions—Infants on ECMO had higher volume of distribution but similar clearance when
compared with historical controls not on ECMO. In infants on ECMO, a fluconazole dose of 25
mg/kg weekly provides adequate exposure for prophylaxis against Candida infections. However,
higher doses may be needed for treatment.
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Extracorporeal membrane oxygenation (ECMO) is a cardiopulmonary bypass device used in
the pediatric critical care setting that is life-saving for infants with refractory
cardiorespiratory failure. Blood is drained from the central venous system via a surgically
placed cannula, pumped through an artificial lung (oxygenator) where oxygen is added and
carbon dioxide is removed, and then oxygenated blood is returned to either the venous or
arterial circulation. ECMO has been used successfully in multiple disease states including
meconium aspiration syndrome, persistent pulmonary hypertension of the newborn,
fulminant myocarditis, and sepsis.1 Despite these successes, infants supported with ECMO
are at high risk for ECMO-related complications, including nosocomial infections.2
Invasive candidiasis is the second most common nosocomial infection in infants on ECMO
and is often fatal.2,3 The incidence of fungal infections in patients on ECMO varies by
center, with reports ranging from 0.7–10%.2,3.Standard treatment for invasive candidiasis in
many patient populations consists of antifungal agents (e.g., fluconazole) and removal or
replacement of intravascular catheters due to the organism’s ability to adhere to indwelling
catheters.4 Catheter removal for infants on ECMO is impossible if the infant cannot be
disconnected from the ECMO circuit; therefore, successful treatment of invasive candidiasis
in infants on ECMO relies upon optimal antifungal drug therapy.
Optimal antifungal management for patients on ECMO depends on dosing that has not been
previously described and can differ greatly from other populations due to the
pharmacokinetic (PK) changes induced by the ECMO circuit. PK changes attributed to the
ECMO circuit include increased volume of distribution and decreased clearance, but these
vary by drug.5–8 This study describes the ECMO-related PK changes of fluconazole and
their impact on pharmacodynamic (PD) targets for fungal prophylaxis and treatment of
invasive candidiasis.
MATERIALS AND METHODS
This was a prospective, single-center, open-label PK and safety trial of fluconazole in
infants supported with ECMO at Duke University Medical Center. Infants <120 postnatal
days and supported with ECMO were enrolled. Infants were excluded if they had a history
of hypersensitivity or severe vasomotor reaction to any triazole or had previously
participated in the study. Infants received either prophylactic fluconazole per study protocol
(25 mg/kg administered intravenously over 2 hours) or fluconazole per standard of care (12
mg/kg administered intravenously over 1 hour) if the child had a known or suspected fungal
infection. Infants on prophylactic fluconazole continued to receive fluconazole 25 mg/kg
once weekly for the duration of their ECMO course. Duration of treatment for infants with
suspected or culture-proven fungal infection was at the discretion of the treating physician.
This trial was approved by the institutional review board of Duke University Medical
Center, registered with clinicaltrials.gov (NCT01169402), and conducted under a Food and
Drug Administration investigational new drug application (#108314). Written informed
consent was obtained from the legal guardian of each infant.
Sample Collection and Preparation
Up to 12 paired samples (200 μL whole blood per sample) were collected from the infant
via an arterial catheter (Cout) and the ECMO circuit just before the oxygenator (Cin) for each
infant at dose 1 and dose 2. Sampling times for all enrolled infants included a trough level
0–4 hours prior to the start of infusion and serial samples after the end of the infusion: 15
minutes (+/−15 minutes), 3 hours (+/−1 hour), 9 hours (+/−3 hours), 23 hours (+/−1 hour),
and 47 hours (+/−1 hour). Samples were collected in ethylenediaminetetraacetic acid
(EDTA) microcontainers and taken from a different site than the site used for fluconazole
administration. Samples were processed immediately or placed on ice until processing.
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Plasma was separated via centrifugation (3000 g for 10 minutes at 4° C), manually aspirated,
and transferred to polypropylene tubes. Plasma samples were frozen at −80° C until
analysis.
Fluconazole extraction by the ECMO oxygenator was calculated using the paired samples
collected from the ECMO circuit just prior to the oxygenator (Cin) and from the patient
(Cout) using the equation: [(Cin − Cout)/Cin] * 100. Any extraction levels greater than 3
standard deviations above or below the mean extraction were considered outliers and were
excluded from the analysis. Venous (Cin) samples were used for all PK analyses.
ECMO Circuit Configuration
The ECMO circuit configuration was consistent across all infants and included tubing (Sorin
Smart®, Sorin Group, Denver, CO), a centrifugal pump (Sorin Revolution®, Sorin Group,
Denver, CO), and a hollow fiber membrane oxygenator (Quadrox-iD Adult® or Quadrox-iD
Pediatric®, MAQUET Cardiovascular, Wayne, NJ). A hemofilter (Sorin DHFO.2®, Sorin
Group, Denver, CO) was used if the infant required hemofiltration or hemodialysis. The
circuit prime volume was 450 mL for the Quadrox-iD Adult® oxygenator (infants 2, 3, 5, 7,
9, 10) and 250 mL for the Quadrox-iD Pediatric® oxygenator (infants 1, 4, 6, 8).
Analytic Procedures and Analyses
Plasma fluconazole concentrations were determined using a validated liquid
chromatography-tandem mass spectrometry assay.9 The lower limit of quantification was
0.01 mg/L; intraday and interday precision ranged from 2.84% to 10.8% and 5.27% to
11.5%, respectively, within the concentration range of the standard curve (0.01 to 10 mg/L).
The primary outcomes were the fluconazole PK indices in infants on ECMO (clearance,
volume of distribution) and the number of infants achieving the proposed PD target for
fungal prophylaxis (fluconazole time above the minimum inhibitory concentration [T>MIC;
4 mg/L] for >50% of the dosing interval).10 In addition, the proportion of infants achieving
the surrogate PD target for treatment (area under the curve from 0–24 hours [AUC0–24] >
400 mg*h/L)11 of invasive candidiasis was calculated. This was performed because the dose
evaluated in this study has previously been evaluated for treatment of candidiasis.12 The
secondary outcome was fluconazole extraction by the ECMO circuit. The PK indices of
fluconazole were examined with descriptive statistics.
PK data were analyzed by nonlinear regression with the most appropriate model using
WinNonlin v. 6.2 (Pharsight Co., St. Louis, MO). The model fit was evaluated using
successful minimization, diagnostic plots, goodness of fit as assessed by the Akaike
Information Criterion, and precision of the parameter estimates. AUC0–24 was computed by
the linear trapezoidal method using simulated data predicted from the 1-compartment model.
The T>MIC was estimated and expressed as a percentage of the dose interval using the
following equation:
where Clast is last simulated fluconazole concentration from the terminal elimination phase
using the predicted data from the 1-compartment model; MIC is the minimum inhibitory
concentration (4 mg/L); k is the elimination rate constant derived from the 1-compartment
model; tlast is time of last fluconazole concentration using the predicted data from the 1-
compartment model; and tMIC is estimated time above the MIC. For an infant on standard-
of-care fluconazole (12 mg/kg daily), AUC0–24 and T>MIC were calculated using the
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simulated data after administration of a 25 mg/kg dose using the clearance and volume of
distribution estimates from the 1-compartment model.
The relationships between fluconazole clearance and serum creatinine on the day of dose, as
well as the fluconazole volume of distribution and the ECMO prime volume were explored
with scatter plots. Differences in PK indices between doses were evaluated using Wilcoxon
signed-rank test. Correlation between ECMO circuit extraction and time was measured with
Spearman’s rank correlation coefficient. The sample size was based on the ability to provide
reasonable estimates for safety. It was determined a priori that, with a sample size of 8, the
95% confidence interval (CI) for an adverse event (AE) in 1 infant within the patient
population was 0–53%. STATA 11 (College Station, TX) was used to perform the statistical
analyses. In all cases, a P value of <0.05 was considered statistically significant.
Safety
The safety of fluconazole was assessed by monitoring the frequency, intensity, and
relationship to study drug of AEs while on study drug and for 7 days after the last dose. The
results of clinical laboratory tests performed within 72 hours of study drug administration
and weekly throughout the monitoring period were recorded. The primary AE of interest
was liver toxicity assessed by the evaluation of aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) values measured at least weekly during study drug
administration. AEs were graded according to the National Cancer Institute’s Common
Terminology Criteria and reported as mild (grade 1), moderate (grade 2), severe (grade 3),
life-threatening (grade 4), or fatal (grade 5). Causality (unrelated and possibly, probably and
definitely related) of AEs and study drug was determined by the principal investigator and
the treating physician. AEs determined to be probably or definitely related to study drug
were followed until resolution. The safety data were summarized descriptively.
RESULTS
Between August 2010 and July 2011, 10 infants with a median age of 19 days (range 1–113
days) supported with ECMO were enrolled in the study, received at least 1 dose of
fluconazole, and were included in the safety analysis (see Table, Supplemental Digital
Content 1, which shows infant demographics). Nine infants received prophylactic
intravenous fluconazole (25 mg/kg weekly infused over 2 hours), and 1 infant (#7) was
treated for presumed fungal infection with standard-of-care fluconazole (12 mg/kg
intravenously daily infused over 1 hour). PK samples were collected from the 9 infants on
prophylaxis around the first dose, and the 6 infants who remained on ECMO for more than 1
week were also sampled around the second dose. Infant #7, who received fluconazole 12
mg/kg/day, had PK samples collected around the final seventh dose. Thirty percent of
infants were female, 60% were white, and 10% were Hispanic. Three infants were born pre-
term. At time of cannulation, median corrected age was 41 weeks (range 36–53 weeks).
Hemofiltration and/or continuous veno-venous hemodialysis (CVVHD) was used in 3
infants. Overall serum creatinine was similar between first dose and multiple dose
evaluations, although 2 infants receiving hemofiltration or CVVHD had a 3-fold increase in
their serum creatinine between dose 1 and 2. The renal dysfunction in infant #3 was
multifactorial, while that in infant #6 was due to intrinsic renal dysfunction following
cardiac arrest. In both cases, renal dysfunction occurred prior to initiation of hemofiltration.
Pharmacokinetics
PK data were evaluated from 62 plasma samples around the first dose and 47 samples after
multiple doses. The plasma concentrations after the first dose and after multiple doses are
shown in Figure 1. The PK indices after first and multiple doses are presented in Table 1. A
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1-compartment model with zero-order infusion appropriately described the data, and PK
indices were estimated with high precision as evidenced by median clearance coefficient of
variation of 10.2% (range 2.0–25.8%) and median volume of distribution coefficient of
variation of 5.7% (range 1.4–16.1%). After the first dose, the median (interquartile range
[IQR]) clearance was 17 mL/kg/h (14, 22), the median volume of distribution was 1.5 L/kg
(1.3, 1.7), and the median AUC0–24 was 322 mg*h/L (307, 343). After multiple doses, the
median (IQR) clearance was 22 mL/kg/h (11, 33), the median volume of distribution was 1.9
L/kg (1.4, 2.2), and the AUC0–24 was 352 mg*h/L (344, 399). Fluconazole clearance was
inversely related to serum creatinine (see Figure, Supplemental Digital Content 2, which
shows weight-normalized fluconazole clearance after dose 1 and multiple doses versus
serum creatinine). Neither fluconazole clearance (P=0.92) nor serum creatinine (P=0.67)
was significantly different between the first and multiple doses. There was no relationship
between the fluconazole volume of distribution and amount of the volume of exogenous
blood needed to prime the ECMO circuit (data not shown). A relationship between postnatal
age and clearance and gestational age and clearance was not observed during visual
inspection of scatter plots (data not shown). The volume of distribution of fluconazole did
not differ significantly between dose 1 and multiple doses (P=0.14). The median fluconazole
trough concentration before dose 2 was 1.8 mg/L (range 0.2–5.4).
Pharmacodynamic Targets
After the first dose, 7 out of 9 infants (78%) achieved the prophylaxis target of T>MIC (4
mg/L) for >84 hours, which was 50% of the dosing interval.10 Only 1 infant (11%) achieved
the therapeutic target for treatment of invasive candidiasis of AUC0–24 > 400 h*mg/L
(Figure 2).11 After multiple doses of fluconazole, 5 out of 7 infants (71%) achieved the
prophylaxis target, and none achieved the therapeutic target. None of the infants developed a
fungal infection while enrolled in the study.
ECMO Circuit Extraction
A total of 210 samples were included in the extraction analysis after 2 paired samples
(1.9%) were identified as outliers and excluded from the analysis.. Mean fluconazole
extraction across the oxygenator was −2.0% (standard deviation 15.0), but there was wide
dispersion around the mean. Extraction by the oxygenator did not correlate with the age of
the ECMO circuit (rho= − 0.05).
Safety
There were 11 adverse events in 6 infants, including 3 deaths. None of the AEs were
probably or definitely related to study drug (see Table, Supplemental Digital Content 3,
which shows adverse events). Three infants had elevated AST or ALT levels. In all 3 cases,
the transaminase levels were elevated prior to initiation of study fluconazole and declined to
normal levels while on study drug. Of the 3 infants who died, 2 of the deaths were attributed
to severe congenital heart disease, and 1 death was attributed to intracranial hemorrhage.
DISCUSSION
Invasive candidiasis can be a devastating complication of ECMO. Invasive candidiasis is
difficult to treat in this setting and is associated with higher mortality compared with infants
on ECMO without invasive candidiasis.2,3 Infants on ECMO with invasive disease require
optimal dosing of antifungal drugs and may benefit from fungal prophylaxis. To prevent or
treat invasive infection, the first step is to determine exposure of a candidate drug. This
requires at least 1 PK and safety study in infants supported by ECMO because the ECMO
circuit can substantially alter the PK of drugs through the addition of large volumes of
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exogenous blood to prime the ECMO circuit, adhesion of drug to components of the ECMO
circuit, and renal insufficiency common in infants on ECMO.13
The complexity of the ECMO circuit and its impact on dosing have been observed for drugs
that require therapeutic drug monitoring such as gentamicin7,14–16 and vancomycin.8,17,18
PK data of antifungals in ECMO, however, are extremely scarce. Two case reports
suggested that voriconazole and caspofungin may be extracted by the ECMO circuit,
resulting initially in subtherapeutic exposure with standard dosing, although voriconazole
concentrations became supra-therapeutic over time, consistent with decreased clearance.19,20
The voriconazole data were supported by an ex vivo ECMO model indicating that 71% of a
voriconazole dose was adsorbed by the ECMO circuit within 3 hours of administration.21
In this PK trial of fluconazole in infants on ECMO, volume of distribution was 50–90%
higher and clearance was similar in infants on ECMO compared with a similar cohort of
critically ill infants not on ECMO,12 resulting in lower fluconazole exposure (AUC0–24)
(Table 2). The increased volume of distribution in infants on ECMO is consistent with
physiology: infants have a total blood volume of ~80 mL/kg (estimated range for our cohort
160–500 mL), and 250–450 mL of blood are required to prime the ECMO circuit. Thus, the
circuit effectively doubles the native blood volume of these infants. Clearance was inversely
related to serum creatinine. This relationship was also expected as the kidneys constitute the
primary fluconazole elimination pathway. Therefore, renal function should be considered
when dosing fluconazole in this population. However, fluconazole clearance can be affected
by the concurrent use of hemofiltration or CVVHD. In adults supported with CVVHD,
higher doses of fluconazole were required to maintain adequate exposure due to effective
drug removal by the CVVHD system.22 Three of the infants enrolled in the present study
received hemofiltration, and 1 received CVVHD. While the small sample size limits
generalization of results (these 3 infants had the lowest, median, and highest fluconazole
clearances, respectively), infant #3 who was supported with both hemofiltration and
CVVHD had a threefold rise in serum creatinine between the start of dose 1 and start of dose
2, the lowest clearance, and the highest volume of distribution. This pattern of renal
insufficiency is common in children on ECMO and supports the hypothesis that, for renally
cleared drugs, a larger dose administered less frequently is appropriate.
Fluconazole undergoes minimal extraction by the ECMO circuit, and that extraction is not
influenced by the age of the ECMO circuit. This finding is consistent with the low
lipophilicity of fluconazole. Prior studies of drugs administered during ECMO have shown
that increased lipophilicity is associated with increased adsorption by the circuit.23
Therefore, the findings from this study should not be extrapolated to other antifungal agents
within and outside of class. Echinocandins have excellent activity against Candida species
and penetrate biofilms, an appealing quality in a population for whom catheter removal is
impossible. However, as a class, they are nearly 100% protein-bound and highly lipophilic,
which may predispose them to high adhesion to the ECMO circuit.
PK/PD indices for fluconazole prophylaxis are not well defined. Dosing for fluconazole
prophylaxis in immuno-compromised adults ranges from 50–200 mg/day, targeting an
AUC0–24 of 50–200 mg*h/L, though with these strategies some resistance to fluconazole has
developed. In premature infants, doses of 3–6 mg/kg given daily twice per week have been
shown to decrease the incidence of invasive candidiasis without concurrent development of
resistance, though the power to detect differences in resistance in these studies was low.24–26
A murine model of invasive candidiasis showed that resistance could be prevented if
fluconazole serum concentrations were kept above the MIC for >50% of the dosing
interval.10 The typical MIC of Candida species in children ranges from 0.25 to 4 mg/L.24–27
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In this trial of fluconazole prophylaxis of infants on ECMO, fluconazole 25 mg/kg weekly
resulted in exposures comparable to those seen in prophylaxis trials in adults and children
with malignancy28 and premature infants.24–26 Further, at this dose, fluconazole serum
concentrations were kept above the MIC of 4 mg/L for 50% of the dosing interval in over
70% of infants on ECMO. Fluconazole 25 mg/kg weekly should be adequate to prevent
invasive candidiasis in infants supported with ECMO and prevent development of
resistance.
However, a fluconazole dose of 25 mg/kg did not achieve the necessary exposure to treat
invasive candidiasis (AUC0–24 >400 mg*h/L) in this population on ECMO. This is in
contrast to a cohort of critically ill children not on ECMO, in whom this therapeutic target
was achieved in 70% of infants who received a fluconazole loading dose of 25 mg/kg.12
Fluconazole PK is linear up to 40 mg/kg;29,30 thus, a fluconazole loading dose of 30–40 mg/
kg would be needed to achieve an AUC0–24 effective to treat Candida infection in infants on
ECMO. Only 1 infant in this study received daily fluconazole treatment doses (12 mg/kg/
day), which limits the assessment of exposures achieved after repeat daily dosing. A
fluconazole therapeutic regimen should be prospectively evaluated.
The decision to use fluconazole prophylaxis in children on ECMO should be based on
individual risk factors and center-specific incidence of fungal infection. The overall rate of
fungal infection for all ECMO centers is relatively low at 2 per 1000 ECMO days.2
Prophylaxis for a low-prevalence infection must be weighed against the devastating
consequences of and difficulty treating a fungal infection in this population.3 A multi-center
trial evaluating the epidemiology of fungal infection and efficacy of antifungal prophylaxis
in children on ECMO is urgently needed.
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Fluconazole concentration time profiles. A. Dose 1: Plasma concentration-time profiles in
young infants (n=9) after receiving first dose of intravenous fluconazole 25 mg/kg.
Concentrations at time=0 hours are concentrations prior to first dose. Pharmacodynamic
(PD) target for prevention of fungal infection is serum concentration > minimum inhibitory
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concentration (MIC) (4 mg/L) for 84 hours (50% of the dosing interval). B. Dose 2: Plasma
concentration-time profiles in young infants after receiving second dose of intravenous
fluconazole 25 mg/kg (n=6). Infant #7 who received treatment fluconazole (12 mg/kg daily)
is not represented in this figure. Concentrations at time=0 hours are trough concentrations
prior to the second dose. PD target for prevention of fungal infection is serum concentration
>MIC (4 mg/L) for 50% of the dosing interval, which was 84 hours for the once-weekly 25
mg/kg dose.
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Median (interquartile range) fluconazole exposure in the first 24 hours (AUC0–24) after dose
1 and multiple doses. Pharmacodynamic target for therapy is AUC0–24 >400 h*mg/L.
AUC0–24 indicates area under the curve from 0–24 hours.
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TABLE 2
Pharmacokinetic Indices in Infants on ECMO after the First Dose of Intravenous Fluconazole 25 mg/kg
Compared with Historical Controls not on ECMO who Received 1 Dose of Intravenous Fluconazole 25 mg/
kg12
ECMO Non-ECMO P
V (L/kg) 1.5 (1.3, 1.7) 1.0 (0.8, 1.4) 0.02
CL (ml/h/kg) 17 (14, 22) 18 (14, 22) 0.57
t1/2 (h) 60 (47, 76) 39 (24, 79) 0.49
AUC0–24 (h*mg/L) 322 (307, 343) 476 (366, 492) 0.01
Data for historical controls were extracted from Piper et al. minus their infant on ECMO and compared using Wilcoxon signed-rank test.
ECMO indicates extracorporeal membrane oxygenation; V, volume of distribution; CL, clearance; t1/2, half-life; AUC0–24,area under the curve
from 0–24 hours. All values are median (interquartile range).
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